Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the granting of a previously disclosed inducement award to the Company’s newly appointed Chief Financial Officer, Scott Coiante....
Toggle Summary Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief Commercial Officer Amy Welsh will present at the H.C....
Toggle Summary Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to First Quarter 2023 Gross Margin Grows to 58% in Second Quarter 2023 from 47% in First Quarter 2023...
Toggle Summary Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before the market open on Wednesday, August 9, 2023....
Toggle Summary Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of MMCAP Infuse, effective July 1, 2023 MMCAP Infuse has over 26,000 member facilities in all 50 states Impact of availability to MMCAP Infuse is expected to augment future non-retail...
Toggle Summary Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
PRINCETON, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today praised the Executive Order issued by President Biden that addresses barriers in access to high quality contraceptive care and family planning services....
Toggle Summary Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
FPA Women’s Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch dispensed within FPA clinics in California Impact of availability through FPA Women’s Health is...
Toggle Summary Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™ Partnership Expected to Augment Future Growth in the Retail Channel, the Company’s Most-Profitable Channel Expanding Commercial Reach through Strategic Partnerships...
Toggle Summary Agile Therapeutics Announces Closing of $7.5 Million Public Offering
PRINCETON, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its previously announced public offering of an aggregate of 1,896,286 shares of its common stock (or...
Toggle Summary Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
PRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock (or pre-funded warrants in lieu...
Shadow